Tina Tehranchian, Award-Winning Senior Wealth Advisor for Assante Capital Management Ltd. was recently selected as Senior Wealth Advisor of the Decade for 2021 by the International Association of Top Professionals (IAOTP)
Toronto, Ontario (PRUnderground) March 9th, 2021
Tina Tehranchian, Award-Winning Senior Wealth Advisor for Assante Capital Management Ltd. was recently selected as Senior Wealth Advisor of the Decade for 2021 by the International Association of Top Professionals (IAOTP). Tina is the first woman and the first Canadian to receive this distinction.
While inclusion with the International Association of Top Professionals is an honor in itself, only one Senior Wealth Advisor is selected for this distinction. Tina is being recognized for this honor for pursuing excellence in every aspect of her business over three decades of professional experience as a licensed and trusted, Senior Wealth Advisor. IAOTP is incredibly honored to be able to recognize Tina for her su
Posted on 422
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA
® (zanubrutinib) has been approved by Health Canada for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
“BRUKINSA is a highly selective BTK inhibitor designed to provide deep and durable response for patients with hematologic malignancies while reducing the frequency of certain side effects. With today’s approval, we are looking forward to bringing this potentially best-in-class BTK inhibitor to Canadians affected by WM,” said Josh Neiman, Chief Commercial Officer for North America and Europe at BeiGene. “We are committed to working to ensure access for patients in Canada and to making BRUKINSA available to patients in more markets worldwide.”
Press release content from Business Wire. The AP news staff was not involved in its creation.
Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia
March 2, 2021 GMT
CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) Mar 2, 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA ® (zanubrutinib) has been approved by Health Canada for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
“BRUKINSA is a highly selective BTK inhibitor designed to provide deep and durable response for patients with hematologic malignancies while reducing the frequency of certain side effects. With today’s approval, we are looking forward to bringing this potentially best-in-class BTK inhibitor to Canadians affected by WM,” said Josh Neiman, Chief Commercial Officer for North America and Euro
Scientists discover two unique subtypes of a prominent mutation in patients with AML
Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with Acute Myeloid Leukemia (AML) – called NPM1 – that could help predict survival and improve treatment response for patients whose leukemic cells bear the mutation.
In research published Feb. 16, in
Nature Communications, a team led by Princess Margaret Cancer Centre Senior Scientists, Drs. Benjamin Haibe-Kains, Aaron Schimmer and Mark Minden, have discovered that within the NPM1 mutation of AML there exists two unique subtypes, one of which can be effectively treated with drugs already in use.
/CNW/ - EMD Serono Canada, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Canada ULC announced that Health.